AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 241 min read$TEM

LEFKOFSKY ERIC P sold $19.4M of TEM (indirect holdings)

LEFKOFSKY ERIC P (CEO and Chairman) sold 250,000 indirectly-held shares of Tempus AI, Inc. (TEM) at an average of $77.47 ($76.57–$78.86, $19.37M total) across 16 trades on 2026-09-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · LEFKOFSKY ERIC P
Published Sep 24, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 8:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TEM
Bearish
medium confidence
Mentioned
$TEM
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMBearishLow
01

Why it matters

The CEO's sizable sell may influence short‑term price action and investor sentiment.

02

Market read

Insider sell is a primary disclosure with moderate materiality, offering limited but actionable insight for traders.

03

What to watch

Potential upcoming financing round or strategic partnership that prompted the insider to free up cash.

Relevance 6/10Novelty 7/10Timing: post-market 2026-09-22

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$TEMBearishMedium confidence
Context

CEO Eric Lefkofsky sold 250,000 shares for $19.4M, reducing his stake to 100,000 shares via a 10b5-1 plan.

Expected impact

Potential short-term downside pressure, 2-4% decline over the next few days.

Evidence & confidence

Insider sales of this magnitude from a founder/CEO often precede negative sentiment, especially when holdings drop by 60%.

Market effects

Sector

May weigh on AI and health‑tech sector sentiment as investors watch founder activity.

Regional

Limited to US markets; no broader regional effect.

Global

Minimal global impact beyond Tempus AI shareholders.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to fundamentals; the stock may remain stable.

Key entities

  • company
    Tempus AI, Inc.

    AI-driven healthcare data platform listed on Nasdaq under ticker TEM.

  • person
    Eric Lefkofsky

    CEO and Chairman of Tempus AI, 10% owner.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TEM insider trading history →

Related articles

OCT 26
$TEMMed

What Happens To Tempus AI Stock If Its Cash Burn Continues?

Tempus AI (TEM) expects positive free cash flow by year-end but had a $273M cash burn over the past year. With $816M in cash, the company's reserves could last about three years at current burn rates. Revenue grew 20% and 36% in diagnostics and data businesses, respectively. Management raised 2026 revenue guidance to $1.595B-$1.605B and issued $460M in convertible notes. The company plans to acquire Personalis, potentially using debt to fund the deal.

finance.yahoo.com2 min
OCT 26
$BMYMed

Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions

Pathos AI has partnered with Bristol Myers Squibb (BMY) and Tempus (TEM) to advance AI-driven drug development for Alzheimer’s and other neurological conditions. Tempus will create a dataset from hundreds of thousands of patients, which Pathos will license for $55 million over five years. BMY leads Pathos's Series E financing and gains access to Pathos's AI platform, Pathos Foundry, for its R&D portfolio, with exclusive rights in neuroscience for three years.

biospace.com3 min
OCT 24
$BMYMed

Tempus Sets $55 Million Ceiling for Pathos Neurology Data Contract

Tempus AI signed a five-year neurology data deal with Pathos AI, potentially worth $55 million. Tempus will deliver up to 500,000 records, with Pathos paying $100 per record. Bristol Myers Squibb gains nonexclusive Foundry access and three-year exclusive rights for neuroscience development. Tempus also has a $137.5 million oncology deal with BMS, totaling $192.5 million if both deals reach full value.

econotimes.com2 min
OCT 23
$TEMMed

Tempus AI Gains 6% as Bristol Myers Squibb Licenses Oncology Data

Tempus AI shares rose 6% after Bristol Myers Squibb agreed to a multi-year deal to license its oncology data through 2031. Tempus's data and AI platform will support BMS's drug discovery and development. Data licensing is Tempus's most profitable segment, with 36% revenue growth in Q2. The financial terms of the deal were not disclosed.

finance.yahoo.com2 min